Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 951.17M | 965.26M | 1.22B | 1.34B | 1.21B | 897.02M |
Gross Profit | 6.98M | 9.72M | 15.65M | -27.55M | 67.78M | 52.86M |
EBITDA | -24.63M | -26.76M | 2.60M | -12.75M | 61.89M | 51.15M |
Net Income | -58.94M | -58.98M | -28.00M | -41.60M | 46.08M | -17.28M |
Balance Sheet | ||||||
Total Assets | 402.21M | 401.44M | 454.24M | 478.32M | 484.95M | 476.82M |
Cash, Cash Equivalents and Short-Term Investments | 26.78M | 35.47M | 30.01M | 36.46M | 50.61M | 47.67M |
Total Debt | 131.27M | 114.67M | 105.46M | 87.27M | 63.65M | 108.23M |
Total Liabilities | 188.29M | 176.38M | 174.68M | 170.23M | 139.74M | 180.58M |
Stockholders Equity | 213.92M | 225.06M | 279.56M | 308.09M | 345.21M | 296.24M |
Cash Flow | ||||||
Free Cash Flow | -30.14M | -14.59M | -7.51M | -31.70M | 10.44M | 65.20M |
Operating Cash Flow | -23.18M | -3.52M | 22.02M | 6.05M | 26.82M | 71.78M |
Investing Cash Flow | -15.23M | -13.47M | -33.03M | -37.66M | 27.12M | 23.32M |
Financing Cash Flow | 23.51M | 7.72M | 6.96M | 19.01M | -40.00M | -66.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $868.90M | 16.36 | 10.68% | ― | -18.36% | -13.81% | |
64 Neutral | $682.34M | 29.78 | 5.08% | 0.94% | -4.09% | -66.97% | |
58 Neutral | $456.49M | ― | -12.34% | ― | -19.82% | -34.91% | |
53 Neutral | $95.74M | ― | -24.43% | ― | -17.27% | -112.62% | |
53 Neutral | $359.34M | ― | -16.11% | ― | 145.38% | -22.02% | |
46 Neutral | $112.65M | ― | 103.25% | 1.33% | -5.28% | 51.91% | |
43 Neutral | AU$1.42B | -6.13 | -40.62% | 4.05% | -4.78% | -42.91% |
On June 23, 2025, Alto Ingredients, Inc. received a notification from Nasdaq confirming that the company’s stock price had met the minimum requirement of $1.00 per share for 10 consecutive business days, thus regaining compliance with Nasdaq’s listing rules. This development ensures the company’s continued listing on the Nasdaq Stock Market, which is crucial for maintaining investor confidence and market presence.
The most recent analyst rating on (ALTO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Alto Ingredients stock, see the ALTO Stock Forecast page.
On June 25, 2025, Alto Ingredients, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. The meeting resulted in the election of six directors, approval of executive compensation, a recommendation for the frequency of advisory votes on executive compensation, and the ratification of RSM US LLP as the independent accounting firm for 2025.
The most recent analyst rating on (ALTO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Alto Ingredients stock, see the ALTO Stock Forecast page.
On May 19, 2025, Alto Ingredients, Inc. received a notification from Nasdaq indicating that its stock price had fallen below the minimum required for continued listing. The company has until November 15, 2025, to regain compliance by ensuring its stock price closes at or above $1.00 for at least 10 consecutive business days. If unsuccessful, Alto may qualify for an additional 180-day period to meet the requirements, potentially involving a reverse stock split. Failure to comply could result in delisting, though the company can appeal such a decision.
The most recent analyst rating on (ALTO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Alto Ingredients stock, see the ALTO Stock Forecast page.